Combining the FAK inhibitors with anti-PD-1antibodies demonstrated enhanced anti-cancer effects in C57BL/6 J primary hepatocellular carcinoma model with complete immune function, reducing Tregs and TAMs while increasing CD8+ T cell population (Wei et al., 2021). This evidence concerns the gene CD8A and cancer.